| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Bruker Corporation$62.84
-1.5 (-2.33%)
F 17Pipeline Score Tools & Services · Commercial
Market Cap
6.96 B
EPS
-0.24
P/E Ratio
-
Value Trade
268.61 M
SEC Financials
Q1 2026Dilution Risk
Revenue
823.40 M
R&D Expenses
101.30 M
Operating CF
71.20 M
Total Assets
6.13 B
Total Liabilities
6.13 B
Equity
2.47 B
D/E Ratio
12,345
4.08 %
Week
12.62 %
1 Month
19.26 %
3 Month
3.37 %
6 Month
-34.67 %
5 Year
123.22 %
All Time
Cash Data
Cash Position
137.60 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.73 M
52 Week Range
28.53 - 56.22
% held by Insiders
27.01 %
% held by Institutions
90.99 %
Enterprise Value
8.55 B
Total Shares
152.12 M
Short %
13.16 %
Float Shares
111.20 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 17%
Small Cap (rank 759 of 913)
Percentile RankBruker Corporation has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BRKR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BRKR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-09-18 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BRKRBruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
Bruker Corporation has announced that it will release its second quarter 2026 financial results on August 4, 2026, before the market opens. Following the release, the company will host a conference call and webcast at 9:00 a.m. EDT to discuss the results and current business trends. Investors can access the webcast through the company's investor relations website.
Read more →BRKRBruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
Bruker Corporation has acquired the DISQVER® clinical metagenomics platform from Noscendo GmbH. This acquisition enhances Bruker's capabilities in infection detection through metagenomic next-generation sequencing (mNGS). The DISQVER® platform enables the analysis of microbes directly from blood samples without prior cultivation, utilizing advanced bioinformatics.
Read more →BRKRBruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry
Bruker has introduced the timsMRMS mass spectrometry platform aimed at addressing unique ultra-complex mixture applications in the energy sector. This launch highlights Bruker's commitment to advancing analytical technology. The new platform is expected to enhance the capabilities of researchers and professionals working with complex mixtures in energy-related fields.
Read more →BRKRBruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
Bruker has announced significant advancements in 4D proteomics, focusing on intact and top-down functional proteoform analysis. These innovations are designed to enhance the understanding of disease biology. The company's developments in hybrid qual/quant 4D metabolomics further support this goal, promising deeper insights for researchers.
Read more →BRKR▲ +11.3%on this news
Bruker Reports First Quarter 2026 Financial Results
Bruker Corporation reported its Q1 2026 financial results, revealing revenues of $823.4 million, a 2.7% increase from the previous year. Despite facing challenges such as decreased organic revenue and tariff pressures, the company noted strong bookings in its BSI segment and reaffirmed its FY26 guidance. The introduction of new products at recent conferences has further solidified its market position.
Read more →BRKRBruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
Bruker Corporation has announced that it will release its first quarter 2026 financial results on May 6, 2026, before market opening. A conference call and webcast will follow at 8:00 a.m. Eastern Time to discuss these results and business trends. Investors can pre-register for the call to streamline their participation.
Read more →BRKRBruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
Bruker has announced significant enhancements to its microbial identification and outbreak management solutions at ESCMID Global 2026. Key updates include the introduction of the MBT Easy T® Kit for streamlined workflows, expansion of reference libraries, and the launch of a cloud-based MALDI identification solution. These innovations aim to improve laboratory efficiency and address evolving infectious disease challenges.
Read more →BRKRBruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
Bruker has announced the launch of its MyGenius PRO® system, a high-throughput sample-to-answer molecular diagnostics system, at the ESCMID 2026 event. This system aims to enhance diagnostic capabilities in molecular testing. Further details on its features and applications were not provided in the article.
Read more →BRKRBruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
Bruker Spatial Biology presented high fidelity spatial data and integrated multi-platform workflows at AACR 2026. The focus was on delivering unprecedented multiomic insights. However, specific details about the findings or technologies were not provided in the article.
Read more →BRKRBruker Unveils New NMR Products and Workflow Solutions at ENC 2026
Bruker has introduced new NMR products and workflow solutions at the ENC 2026 event. The announcement highlights the company's commitment to advancing nuclear magnetic resonance technology. Details on the specific products and their applications were not disclosed in the article.
Read more →BRKRBruker Invests in Photothermal AFM-IR to Advance Semiconductor Research
Bruker has made an investment in photothermal AFM-IR technology aimed at enhancing semiconductor research. This move is expected to bolster their capabilities in this field. Further details on the specific applications or expected outcomes of this investment were not provided in the article.
Read more →BRKRBruker Announces Appointment of Thierry Bernard to its Board of Directors
Bruker Corporation has appointed Thierry L. Bernard to its Board of Directors, effective immediately. Bernard, currently the CEO of QIAGEN, has a strong background in the life-science tools and diagnostics industry. His experience is expected to contribute to Bruker's growth in life-science research and diagnostics. Bernard expressed enthusiasm about joining the board and supporting Bruker's mission.
Read more →BRKRBruker Accelerates the Future of Diagnostic and Prognostic Spatial Proteomics with the Launch of CellScape XR
Bruker Corporation has launched CellScape XR, a cutting-edge spatial proteomics platform aimed at enhancing diagnostic and prognostic assay development. This platform addresses key challenges in translational research by providing high-throughput and reproducible spatial proteomics. Collaborations, such as with the University Hospital Schleswig-Holstein, are set to analyze thousands of patient samples, furthering the platform's clinical applications.
Read more →BRKRBruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications
Bruker Corporation is expanding its collaboration with Noetik Inc. to enhance tissue foundational models for therapeutic applications. This partnership aims to leverage advanced AI models and the CosMx Spatial Molecular Imager to generate extensive datasets for drug discovery. The collaboration seeks to scale data significantly, potentially reaching one billion spatially resolved human cells, which could transform oncology research.
Read more →BRKRBruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum
Bruker Corporation announced significant advancements in spatial biology at the AGBT 2026 meeting. The company will unveil new products, including the PaintScape platform for 3D genome visualization and the CellScape XR for spatial proteomics. These innovations aim to enhance research capabilities across DNA, RNA, and protein, further integrating multiomics. Additionally, Bruker is collaborating with the University of Glasgow to create a Spatial Biology Center of Excellence.
Read more →BRKRBruker Advances Functional Proteomics 2.0 with timsOmniTM Mass Spectrometry Proteoform Analysis for Deeper Insights into Disease Biology
Bruker Corporation has announced advancements to its timsOmni mass spectrometer, enhancing Functional Proteomics 2.0 workflows. New software releases support database-independent PTM discovery and proteoform characterization, enabling deeper insights into disease biology and drug discovery. The integration of AI in peptide sequencing further enhances the accuracy and efficiency of proteomics research.
Read more →BRKR▼ -11.6%on this news
Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
Bruker Corporation reported its financial results for Q4 and FY 2025, indicating a slight revenue decrease but an optimistic outlook for FY 2026. The company noted a recovery in biopharma and industrial research markets, leading to better-than-expected Q4 revenues. Management anticipates significant operating margin expansion and double-digit EPS growth in the upcoming fiscal year.
Read more →BRKRChemspeed and SciY Announce Self‑Driving Laboratory Platform Integrating Automation, Analytics and AI Orchestration
Chemspeed Technologies and SciY have launched a Self-Driving Lab (SDL) platform aimed at enhancing R&D and QC workflows through AI orchestration and automation. This platform addresses common laboratory challenges by integrating various systems and providing a unified data environment. The initiative has garnered significant interest from pharmaceutical partners, indicating a demand for scalable, autonomous lab solutions.
Read more →BRKRBruker Announces Quarterly Preferred Stock Dividend
Bruker Corporation has announced a quarterly cash dividend of $3.9844 per share on its 6.375% Mandatory Convertible Preferred Stock. This dividend will be paid on March 2, 2026, to stockholders of record as of February 15, 2026. The announcement underscores Bruker's commitment to returning value to its shareholders.
Read more →BRKRBruker Announces Date and Time of Fourth Quarter 2025 Earnings Release and Webcast
Bruker Corporation has announced the date for its fourth quarter and fiscal year 2025 earnings release, scheduled for February 12, 2026. A conference call and webcast will follow at 8:30 a.m. EST to discuss the results and business trends. Investors can pre-register for the call to streamline their participation.
Read more →BRKRBruker Announces Orders for High-Performance Magnetic Resonance Systems for Materials and Life-Science Research from Leading European Institutions
Bruker Corporation announced substantial orders for high-performance magnetic resonance systems from leading European research institutions. The orders, totaling around $25 million, include advanced NMR systems aimed at enhancing research in drug discovery, battery materials, and disease biology. Revenue recognition for these orders is expected over fiscal 2026 and 2027.
Read more →BRKRBruker announces the addition of Diagnostics Industry leader Jack Phillips to its Board of Directors as of January 2026
Bruker Corporation has appointed Jack Phillips to its Board of Directors, effective January 1, 2026. Phillips is an experienced executive in the diagnostics sector, having served as CEO of Accelerate Diagnostics and Roche Diagnostics North America. His strategic experience and leadership in developing innovative diagnostic technologies are expected to contribute significantly to Bruker, particularly in expanding its infectious disease diagnostics portfolio. Phillips expressed enthusiasm for joining Bruker and leveraging his vision for connected diagnostics.
Read more →BRKRBruker Reports Third Quarter 2025 Financial Results • Q3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically • Q3 2025 GAAP diluted loss per share $(0.41); non-GAAP dilute
Bruker Corporation reported its financial results for Q3 2025, highlighting revenues of $860.5 million, a 0.5% decrease from the same quarter last year. The company experienced a GAAP diluted loss per share of $(0.41) and updated its fiscal year 2025 revenue guidance downward, reflecting ongoing market challenges. However, there was an increase in organic bookings and successful new product launches in the biopharma sector. Overall, while Q3 performance showed some encouraging signs, it was marred by significant losses and revenue declines.
Read more →BRKR▼ -8.6%on this news
Bruker Reports Second Quarter 2025 Financial Results • Q2 2025 revenues of $797.4 million, down 0.4% year-over-year (yoy); organic revenue down 7.0%, and constant-exchange rate (CER) revenue down 3.3% • Q2
Bruker Corporation reported its second quarter financial results, indicating a small revenue decline of 0.4% year-over-year at $797.4 million, with organic revenue down 7.0%. The company announced a cost-saving initiative aiming to cut annual expenses by $100 to $120 million in FY 2026 in response to current market pressures. Moreover, Bruker is optimistic about a partial recovery in demand by FY 2026, despite revising its FY 2025 guidance lower due to ongoing challenges in the academic and biopharmaceutical markets. Key innovations and acquisition activities are expected to support future growth.
Read more →BRKR▼ -12.1%on this news
Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on
Bruker Corporation announced its preliminary financial results for the second quarter of 2025, revealing expected revenues in the range of $795 to $798 million, reflecting flat growth from the previous year. The company anticipates a decline in non-GAAP organic revenue of approximately 7% year-over-year, largely attributed to weak academic demand and challenges in the U.S. biopharma market. The earnings per share (EPS) is projected to be between $0.32 and $0.34, signifying a decline of about $0.19 compared to the same quarter in 2024. An earnings conference call is scheduled for August 4, 2025, to further discuss these results and ongoing business developments.
Read more →BRKRBruker and 10x Genomics Reach Global Settlement of Patent Litigation BILLERICA, Massachusetts –
Bruker Corporation has announced a global settlement with 10x Genomics to resolve their patent disputes, resulting in the dismissal of multiple lawsuits in various countries including the U.S. and Germany. This agreement allows both companies to focus on their respective research and product development without the distraction of legal battles. Bruker aims to enhance its contributions to the life sciences, particularly in oncology and neurobiology, by providing their CosMx and GeoMx spatial biology platforms without further litigation concerns.
Read more →BRKRBruker Reports First Quarter 2025 Financial Results • Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Inst
Bruker Corporation reported its Q1 2025 financial results, with total revenues of $801.4 million, up 11.0% from the previous year. The company noted a 5.1% organic revenue increase within its Bruker Scientific Instruments segment. However, both GAAP and non-GAAP diluted EPS experienced declines due to M&A challenges. Bruker has adjusted its FY 2025 revenue and EPS guidance, citing US policy changes and tariff impacts as significant factors affecting financial outlook.
Read more →BRKRBruker Announces First Quarter 2025 Preliminary Revenue BILLERICA, Massachusetts—
Bruker Corporation has announced preliminary revenue figures for the first quarter of 2025, projecting a range between $795 million and $800 million, which surpasses prior forecasts and consensus expectations. This reflects an estimated annual revenue growth of around 10%, with notable performance in the Bruker Scientific Instrument segment. However, the company also notes a high-teens percentage decline in its BEST segment. Financial detailed reports are expected to be released on May 7, 2025, alongside a conference call with investors.
Read more →BRKRBruker Appoints Laura Francis to its Board of Directors
Bruker Corporation has appointed Laura Francis to its Board of Directors, effective February 18, 2025. Ms. Francis, the CEO of SI-BONE, Inc., will also join Bruker's Audit Committee post the annual shareholder meeting in May 2025. Her extensive background in the life sciences and medtech industries is expected to contribute positively to Bruker's growth strategy. The company's leadership has expressed their confidence in her capabilities to drive innovation and success within the organization.
Read more →BRKRBruker Reports Fourth Quarter and Full Year 2024 Financial Results • Q4 2024 revenues of $979.6 million, up 14.6% year-over-year (yoy); Bruker organic revenue up 3.9%, and constant-exchange rate (CER) revenue up 1
Bruker Corporation reported impressive financial results for Q4 and FY 2024, with revenues reaching $979.6 million in Q4, a 14.6% year-over-year increase. The company achieved solid organic revenue growth, bolstered by successful integration of recent acquisitions. Despite a decline in GAAP diluted EPS, Bruker has provided optimistic guidance for FY 2025, forecasting revenue growth of 3% to 5% and a significant increase in non-GAAP EPS. Overall, Bruker is positioning itself for continued growth, thanks to its strategic initiatives.
Read more →BRKRBruker Reports Third Quarter 2024 Financial Results • Q3 2024 revenues of $864.4 million, up 16.4% year-over-year (yoy); Bruker organic revenue up 3.1% yoy, and CER revenue up 15.7% yoy; BSI segment organic revenu
Bruker Corporation (BRKR) has reported its Q3 2024 financial results, showing a revenue increase of 16.4% year-over-year, totaling $864.4 million. The company's organic revenue growth stood at 3.1%, with a constant-exchange rate (CER) revenue growth of 15.7%. Despite these positive results, Bruker has adjusted its FY2024 guidance downward due to delays in biopharma and China recoveries, lowering organic revenue growth expectations to 3-4%. The company also noted a decrease in GAAP diluted EPS compared to the previous year.
Read more →BRKRBruker Reports Second Quarter 2024 Financial Results • Q2 2024 revenues of $800.7 million, up 17.4% year-over-year (yoy); organic revenue up 7.4% yoy; CER revenue up 18.5% yoy • Q2 2024 GAAP EPS $0.05; non-
Bruker Corporation reported its financial results for Q2 2024, showing total revenues of $800.7 million, an increase of 17.4% year-over-year. The company raised its full-year revenue guidance to between $3.38 billion and $3.44 billion, reflecting anticipated growth driven by recent acquisitions. While the company experienced organic revenue growth and solid EPS increases, it faced challenges with decreased GAAP operating income and operating margins. The outlook remains optimistic, with significant growth strategies in place as Bruker navigates the market landscape.
Read more →BRKRBruker Announces Public Offering of Common Stock
Bruker Corporation announced a public offering of 6,000,000 shares of its common stock, with an option for underwriters to purchase an additional 900,000 shares. The proceeds from this offering are intended for debt reduction related to recent acquisitions. It is noted that the offering is subject to market conditions and other customary closing criteria, raising uncertainty about its completion and final terms. BofA Securities and J.P. Morgan are serving as joint underwriters for the offering.
Read more →BRKR▼ -11.3%on this news
Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech • ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems
Bruker Corporation has successfully completed the acquisition of ELITechGroup, a provider of molecular diagnostics systems and assays, for €870 million. This merger aims to enhance Bruker's offerings in the infectious disease diagnostics market, particularly in Europe and the Americas. The integration of ELITech will create the Bruker Molecular Diagnostics business, expected to generate approximately $100 million in revenue for Bruker in 2024. While the acquisition offers substantial growth opportunities, it also carries risks associated with business integration and market performance.
Read more →BRKR▼ -11.3%on this news
Bruker Reports First Quarter 2024 Financial Results • Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenue up 5.5% yoy • Q1
Bruker Corporation reported first-quarter 2024 revenues of $721.7 million, marking a 5.3% increase year-over-year. The company has raised its FY 2024 revenue guidance to an expected range of $3.29 to $3.35 billion, reflecting an optimistic outlook. Notably, Bruker closed the acquisition of ELITech, which is anticipated to enhance its diagnostics segment and revenue growth. However, both GAAP operating income and EPS saw declines compared to the previous year, indicating some operational challenges amidst overall positive revenue growth.
Read more →BRKRBruker to Acquire the NanoString Business in an Asset Deal NanoString is an Established Leader and Valuable Innovator in Gene Expression Profiling and Spatial Transcriptomics for Scientific and Clinical Research in Healt
Bruker Corporation has announced a definitive acquisition agreement to purchase NanoString Technologies, with the deal focusing on acquiring substantially all assets associated with NanoString's business. The acquisition, valued at approximately $392.6 million, is expected to close in the second quarter of 2024, subject to customary conditions. Bruker anticipates that the integration will bolster its spatial biology portfolio, although the deal may initially be dilutive to EPS. Despite some uncertainties around NanoString's financial performance, Bruker remains optimistic about future growth and synergies.
Read more →BRKR▲ +8.8%on this news
Bruker Reports Fourth Quarter and Full Year 2023 Financial Results • Q4 2023 revenues of $854.5 million, up 20.6% year-over-year (yoy); organic revenue up 15.9% yoy • Q4 2023 GAAP EPS of $1.41, including a
Bruker Corporation reported its financial results for the fourth quarter and full year of 2023, showcasing robust revenue growth. Q4 revenues reached $854.5 million, a 20.6% increase year-over-year, while full year revenues totaled $2.96 billion, up 17.1%. Despite a decrease in non-GAAP EPS for Q4, Bruker highlighted a strong performance with significant organic revenue growth. The company is optimistic about FY 2024, projecting an 8% to 10% revenue growth and continued innovation in their product offerings.
Read more →BRKRBruker Reports Third Quarter 2023 Financial Results • Q3 2023 revenues of $742.8 million, up 16.3% year-over-year (yoy); organic revenue up 10.9% yoy • Q3 2023 GAAP EPS $0.60; non-GAAP EPS $0.74, up 12.1% y
Bruker Corporation reported strong financial results for Q3 2023, with revenues of $742.8 million, reflecting a 16.3% year-over-year increase. The company raised its revenue guidance for FY 2023 to a range of $2.88-$2.91 billion, driven by robust organic growth. Non-GAAP diluted EPS for the quarter rose to $0.74, demonstrating continued profitability despite a slight decrease in GAAP operating income. Bruker anticipates organic revenue growth of high-single digits for Q4, maintaining its track record of double-digit growth despite challenging market conditions.
Read more →BRKRBruker Reports Second Quarter 2023 Financial Results • Q2 2023 revenues of $681.9 million, up 15.9% year-over-year (yoy); organic revenue up 13.5% yoy • Q2 2023 GAAP EPS $0.39; non-GAAP EPS $0.50, up 11.1%
Bruker Corporation reported strong financial results for the second quarter of 2023, with revenues reaching $681.9 million, marking a 15.9% increase year-over-year. The company also saw an 11.1% rise in non-GAAP diluted earnings per share, prompting an increase in its fiscal year revenue guidance to a range of $2.85-$2.90 billion. While the company has shown robust organic revenue growth, there are concerns regarding a slight decrease in non-GAAP operating margins and adverse foreign currency effects. Overall, Bruker maintains a positive outlook for the second half of 2023.
Read more →BRKRBruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board Declares Quarterly Dividend BILLERICA, Massachusetts –
Bruker Corporation has announced a new two-year share repurchase program, authorizing the purchase of up to $500 million in common stock. This move, aimed at maximizing shareholder value, follows the company's solid financial performance and outlook. Additionally, the Board of Directors declared a quarterly cash dividend of $0.05 per share, to be distributed on June 16, 2023. The new initiatives support Bruker's commitment to investor returns while continuing to fund innovation in high-growth areas.
Read more →BRKRBruker Reports First Quarter 2023 Financial Results • Q1 2023 revenues of $685.3 million, up 15.2% year-over-year (yoy); organic revenue up 17.6% yoy • Q1 2023 GAAP EPS $0.52; non-GAAP EPS $0.64, up 30.6% y
Bruker Corporation reported strong financial results for the first quarter of 2023, with revenues of $685.3 million, a year-over-year increase of 15.2%. The company's non-GAAP earnings per share rose to $0.64, reflecting a 30.6% increase from the previous year. Based on this performance, Bruker has raised its full-year 2023 revenue guidance to between $2.83 billion and $2.88 billion. This outlook suggests continued steady growth driven by strong demand for its scientific instruments and technologies.
Read more →BRKRBruker Reports Fourth Quarter and Fiscal Year 2022 Financial Results • Q4 2022 revenues $708.4 million, up 3.6% year-over-year (yoy); organic revenue growth of 8.9% • Q4 2022 GAAP EPS $0.66; non-GAAP EPS $0
Bruker Corporation announced its financial results for Q4 and FY 2022, reporting revenues of $708.4 million for Q4, reflecting a 3.6% increase year-over-year. The company achieved an organic revenue growth of 8.9% for the same quarter and expects continued growth, projecting 8% to 10% for FY 2023. Despite foreign currency translation adversely affecting revenues, Bruker plans to increase investments in areas such as proteomics and spatial biology to drive future growth. The company also noted significant year-over-year improvements in GAAP and non-GAAP earnings per share.
Read more →BRKR▲ +5.1%on this news
Bruker Reports Third Quarter 2022 Financial Results • Q3 2022 reported revenue growth of 4.9% year-over-year (yoy); organic revenue growth of 12.7% • Q3 2022 GAAP operating margin 20.6%; non-GAAP operating
Bruker Reports Third Quarter 2022 Financial Results -Q3 2022 reported revenue growth of 4.9% year-over-year (yoy); organic revenue growth of 12.7% -Q3 2022 GAAP operating margin 20.6%; non-GAAP operating margin 22.4%, up 180 basis points yoy -Q3 2022 GAAP EPS $0.59; non-GAAP E
Read more →BRKRBruker Reports Second Quarter 2022 Financial Results • Q2 2022 reported revenue growth of 3.1% year-over-year (yoy); organic revenue growth of 8.8% • Q2 2022 GAAP EPS $0.33; non-GAAP EPS $0.45, up 2.3% yoy
Bruker Reports Second Quarter 2022 Financial Results -Q2 2022 reported revenue growth of 3.1% year-over-year (yoy); organic revenue growth of 8.8% -Q2 2022 GAAP EPS $0.33; non-GAAP EPS $0.45, up 2.3% yoy -Maintaining FY 2022 guidance for high, single-digit organic revenue grow
Read more →BRKR▲ +6.3%on this news
Bruker Reports First Quarter Financial Results • Q1 2022 revenue growth of 7.3% year-over-year (yoy); organic revenue growth of 10.5% • Q1 2022 GAAP EPS $0.41; non-GAAP EPS $0.49, up 11.4% yoy • Rais
Bruker Reports First Quarter Financial Results -Q1 2022 revenue growth of 7.3% year-over-year (yoy); organic revenue growth of 10.5% -Q1 2022 GAAP EPS $0.41; non-GAAP EPS $0.49, up 11.4% yoy -Raising fiscal year 2022 organic revenue outlook on strong demand for the Company's h
Read more →BRKR▲ +5.5%on this news
Bruker Appoints Philip Ma to its Board of Directors
Bruker Appoints Philip Ma to its Board of Directors BILLERICA, Massachusetts, March 16, 2022 (BUSINESS WIRE) Bruker Corporation (Nasdaq: BRKR) today announced that its Board of Directors has appointed Philip Ma, Ph.D. to serve on its board, effective as of April 1, 2022. Dr. P
Read more →BRKRBruker Reports Fourth Quarter and Fiscal Year 2021 Financial Results Q4 2021 revenues $683.5M, up 8.9% year-over-year (yoy); organic revenue growth of 11.4% yoy Q4 2021 GAAP EPS $0.50; non-GAAP EPS $0.59, up $0.01 yoy FY
Bruker Reports Fourth Quarter and Fiscal Year 2021 Financial Results BILLERICA, Massachusetts February 11, 2022 Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the fiscal year ended December 31, 2021. Fourth Quarter 2021 Finan
Read more →BRKRBruker Reports Third Quarter 2021 Financial Results Q3 2021 revenues of $608.9 million, up 19.1% year-over-year (yoy); organic growth of 17.8% Q3 2021 GAAP EPS of $0.57, up 63% yoy; non-GAAP EPS of $0.63, up 50% yoy Rais
Bruker Reports Third Quarter 2021 Financial Results BILLERICA, Massachusetts November 1, 2021 Bruker Corporation (Nasdaq: BRKR) today announced financial results for its third quarter and for the nine months ended September 30, 2021. Third Quarter 2021 Financial Results Bruke
Read more →BRKRBruker Reports Second Quarter 2021 Financial Results Q2 2021 revenue growth of 34.4% year-over-year; organic revenue growth of 27.2% Q2 2021 GAAP EPS of $0.38; non-GAAP EPS of $0.44, compared to $0.21 in Q2 2020 Strong f
Bruker Reports Second Quarter 2021 Financial Results BILLERICA, Massachusetts August 2, 2021 Bruker Corporation (Nasdaq: BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2021. Second Quarter 2021 Financial Results revenues f
Read more →BRKRBruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day
Bruker Updates FY 2021 Guidance and Provides Medium Term Outlook at Virtual Investor Day BILLERICA, Mass. June 17, 2021 At its 2021 Virtual Investor Day today, Bruker Corporation (Nasdaq: BRKR) will discuss the Company s strategy and Project Accelerate 2.0 initiatives, includi
Read more →BRKRBruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board also Declares Quarterly Dividend
Bruker Announces New Two-Year Share Repurchase Authorization of up to $500 Million; Board also Declares Quarterly Dividend BILLERICA, Mass. May 13, 2021 Bruker Corporation (Nasdaq: BRKR) today announced that on May 12, 2021, its Board of Directors approved a new share repurcha
Read more →BRKRBruker Reports First Quarter 2021 Financial Results Q1 2021 revenue growth of 30.8% year-over-year, organic revenue growth of 23.8% Q1 2021 GAAP EPS of $0.37; non-GAAP EPS of $0.44, compared to $0.14 in Q1 2020 Raising f
Bruker Reports First Quarter 2021 Financial Results BILLERICA, Massachusetts May 5, 2021 Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2021. Quarter 2021 Financial Results Bruker s revenues for the first quarter of 2
Read more →BRKRBruker Announces First Quarter 2021 Preliminary Revenue
Bruker Announces First Quarter 2021 Preliminary Revenue BILLERICA, Massachusetts April 13, 2021 Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2021 in a range of $549-$554 million, representing reported revenue growth
Read more →BRKRBruker Reports Fourth Quarter and Fiscal Year 2020 Financial Results Q4 2020 revenues up 4.6% year-over-year; organic revenue declines 0.4% Q4 2020 GAAP EPS of $0.45; non-GAAP EPS of $0.58 Expanded Project Accelerate 2.0
Bruker Reports Fourth Quarter and Fiscal Year 2020 Financial Results BILLERICA, Massachusetts - February 16, 2021 - Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the fiscal year ended December 31, 2020. Fourth Quarter 2020
Read more →BRKRThe field allows up to 17 characters.
The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNum
Read more →BRKRBruker Appoints Bonnie H. Anderson to its Board of Directors
Bruker Appoints Bonnie H. Anderson to its Massachusetts - September 8, 2020 - Bruker Corporation (Nasdaq: BRKR) today announced that it has appointed Bonnie H. Anderson to serve on its board of directors, effective as of September 3, "We are very pleased to welcome Bonnie to
Read more →BRKRBruker Reports Second Quarter 2020 Financial Results COVID-19 disruption and softer demand negatively affect Q2 2020 financial results Q2 2020 revenue decline of 13.4% year-over-year; organic revenue decline of 12.7% Q2
Bruker Reports Second Quarter 2020 Financial BILLERICA, Massachusetts - August 3, 2020 - Bruker Corporation (Nasdaq: BRKR) today announced financial results for its second quarter and for the six months ended June 30, 2020. Second Quarter 2020 Financial Results Bruker's reve
Read more →BRKRBruker Reports First Quarter 2020 Financial Results Q1 2020 revenue decline of 8.1% year-over-year, organic revenue decline of 7.9% Q1 2020 GAAP EPS of $0.07, compared to $0.20 in Q1 2019; non-GAAP EPS of $0.14, compared
Bruker Reports First Quarter 2020 Financial - Q1 2020 revenue decline of 8.1% year-over-year, organic revenue decline of 7.9% - Q1 2020 GAAP EPS of $0.07, compared to $0.20 in Q1 2019; non-GAAP EPS of $0.14, compared to $0.28 in Q1 2019 - COVID-19 disruption expected to nega
Read more →BRKRBruker Announces Final Fourth Quarter and Fiscal Year 2019 Financial Results Q4 2019 revenue growth of 8.4%, organic revenue growth of 5.2% year-over-year FY 2019 revenue growth of 9.3%, organic revenue growth of 5.7% ye
Bruker Announces Final Fourth Quarter and Fiscal Year 2019 Financial Results BILLERICA, Massachusetts - March 27, 2020 - Bruker Corporation (Nasdaq: BRKR) today announced final audited financial results for the fourth quarter and fiscal year 2019, and the filing of the Compan
Read more →BRKRBruker Receives Notification from Nasdaq Related to Delayed Annual Report on Form 10-K
Receives Notification from Nasdaq Related to Delayed Annual Report on Form 10-K Massachusetts - March 5, 2020 - Bruker Corporation (Nasdaq: BRKR) today announced that it received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indic
Read more →BRKRBruker Reports Third Quarter 2019 Financial Results Q3-19 revenue growth of 11.7% and organic revenue growth of 7.6% year-over-year Q3-19 GAAP EPS of $0.39; Q3-19 non-GAAP EPS of $0.43, up 16.2% year-over-year Increasing
Reports Third Quarter 2019 Financial Results Q3-19 revenue growth of 11.7% and organic revenue growth of 7.6% year-over-year Q3-19 GAAP EPS of $0.39; Q3-19 non-GAAP EPS of $0.43, up 16.2% year-over-year Increasing FY 2019 non-GAAP EPS outlook to $1.59 to $1.62 BILLERICA,
Read more →BRKRBruker Reports Second Quarter 2019 Financial Results Q2-19 revenue growth of 10.5% and organic revenue growth of 4.8% year-over-year Q2-19 GAAP EPS of $0.23; Q2-19 non-GAAP EPS of $0.33, up 32% year-over-year Confirms FY
Bruker Reports Second Quarter 2019 Financial Results Q2-19 revenue growth of 10.5% and organic revenue growth of 4.8% year-over-year Q2-19 GAAP EPS of $0.23; Q2-19 non-GAAP EPS of $0.33, up 32% year-over-year Confirms FY 2019 revenue growth, non-GAAP operating margin expansion
Read more →BRKRBruker Announces New $300 Million Share Repurchase Authorization and Quarterly Dividend
Bruker Announces New $300 Million Share Repurchase Authorization and BILERICA, Mass. May 10, 2019 Bruker Corporation (NASDAQ: BRKR) today announced that on May 9, 2019, its Board of Directors approved a new share repurchase authorization for the purchase of up to $300 million of
Read more →BRKRBruker Reports First Quarter 2019 Financial Results Q1 2019 revenue growth of 6.9% year-over-year (yoy), organic revenue growth of 5.5% yoy; Q1 2019 GAAP EPS of $0.20; Q1 2019 non-GAAP EPS of $0.28, up 16.7% yoy; Q1 2019
Bruker Reports First Quarter 2019 Financial Results Q1 2019 revenue growth of 6.9% year-over-year (yoy), organic revenue growth of 5.5% yoy; Q1 2019 GAAP EPS of $0.20; Q1 2019 non-GAAP EPS of $0.28, up 16.7% yoy; Q1 2019 GAAP operating margin of 9.1%; Q1 2019 non-GAAP operatin
Read more →BRKRBruker Reports Fourth Quarter and Fiscal Year 2018 Financial Results Q4 2018 revenue growth of 4.4%, FY 2018 revenue growth of 7.3% Q4 2018 organic revenue growth of 3.4%; FY 2018 organic revenue growth of 4.3% Q4 2018 G
Bruker Reports Fourth Quarter and Fiscal Year 2018 Financial Results Q4 2018 revenue growth of 4.4%, FY 2018 revenue growth of 7.3% Q4 2018 organic revenue growth of 3.4%; FY 2018 organic revenue growth of 4.3% Q4 2018 GAAP EPS of $0.50; Q4 2018 non-GAAP EPS of $0.54, up 5.9%
Read more →BRKRBruker Reports Third Quarter 2018 Financial Results
Bruker Reports Third Quarter 2018 Financial Results BILLERICA, Mass. November 1, 2018 Bruker Corporation (NASDAQ: BRKR) today announced financial results for its third quarter and nine months ended September 30, 2018. Bruker s revenues for the third quarter of 2018 were $466.6
Read more →BRKRBruker Reports Second Quarter 2018 Financial Results
Bruker Reports Second Quarter 2018 Financial Results BILLERICA, Mass. August 2, 2018 Bruker Corporation (NASDAQ: BRKR) today announced financial results for its second quarter and six months ended June 30, 2018. Bruker s revenues for the second quarter of 2018 were $443.7 milli
Read more →BRKRBruker Corporation Appoints Gerald Herman as Chief Financial Officer
Bruker Corporation Appoints Gerald Herman as Chief Financial Officer BILLERICA, Massachusetts June 6, 2018 Bruker today announced that it has appointed Gerald N. Herman to serve as the Company s Chief Financial Officer (CFO), effective immediately. Mr. Herman commented: Bruker
Read more →BRKRBruker Reports First Quarter 2018 Financial Results
Bruker Reports First Quarter 2018 Financial Results BILLERICA, Mass. May 3, 2018 Bruker Corporation (NASDAQ: BRKR) today announced financial results for its first quarter ended March 31, 2018. Bruker s revenues for the first quarter of 2018 were $431.7 million, an increase of 1
Read more →BRKRBruker Appoints Gerald Herman as Interim Chief Financial Officer
Bruker Appoints Gerald Herman as Interim Chief Financial Officer BILLERICA, Massachusetts March 14, 2018 Bruker today announced that it has appointed Gerald N. Herman to serve as the Company s Interim Chief Financial Officer (CFO), effective as of March 17, 2018. Mr. Herman was
Read more →BRKRBruker Announces Resignation of Chief Financial Officer and Appointment of Principal Accounting Officer
Bruker Announces Resignation of Chief Financial Officer and Appointment of Principal Accounting Officer BILLERICA, Massachusetts February 21, 2018 Bruker Corporation (NASDAQ: BRKR) today announced that Mr. Anthony L. Mattacchione, Chief Financial Officer (CFO) and Senior Vice Pr
Read more →BRKRBruker Reports Fourth Quarter and Fiscal Year 2017 Financial Results
Bruker Reports Fourth Quarter and Fiscal Year 2017 Financial Results BILLERICA, Mass. February 8, 2018 Bruker Corporation (NASDAQ: BRKR) today announced financial results for its fourth quarter and fiscal year ended December 31, 2017. Bruker s revenues for the fourth quarter of
Read more →BRKRBruker Reports Third Quarter 2017 Financial Results
Bruker Reports Third Quarter 2017 Financial Results BILLERICA, Mass. November 2, 2017 Bruker Corporation (NASDAQ: BRKR) today announced financial results for its third quarter ended September 30, 2017. Bruker s revenues for the third quarter of 2017 were $435.6 million, an incr
Read more →BRKRBruker Reports Second Quarter 2017 Financial Results
Bruker Reports Second Quarter 2017 Financial Results BILLERICA, Mass. August 3, 2017 Bruker Corporation (NASDAQ: BRKR) today announced financial results for its second quarter ended June 30, 2017. Bruker s revenues for the second quarter of 2017 were $414.9 million, an increase
Read more →BRKRBruker Announces New $225 Million Share Repurchase Program and Quarterly Dividend
Bruker Announces New $225 Million Share Repurchase Program and Quarterly Dividend BILLERICA, Mass. May 12, 2017 Bruker Corporation (NASDAQ: BRKR) today announced that its Board of Directors has approved a new share repurchase program authorizing the purchase of up to $225 millio
Read more →BRKRBruker Reports First Quarter 2017 Financial Results
Bruker Reports First Quarter 2017 Financial Results BILLERICA, Mass. May 3, 2017 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its first quarter ended March 31, 2017. Bruker s revenues for the first quarter of 2017 were $384.9 million, an increase of 2.
Read more →BRKRBruker Reports Fourth Quarter and Fiscal Year 2016 Financial Results
Bruker Reports Fourth Quarter and Fiscal Year 2016 Financial Results BILLERICA, Mass. February 13, 2017 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its fourth quarter and fiscal year (FY) ended December 31, 2016. Bruker s revenues for the fourth quart
Read more →BRKRBruker Corporation Bruker drives profitable growth and margin expansion by enabling scientific discoveries and by delivering high-performance analytical, life science and diagnostic solutions Innovation with Integrity Br
Bruker Corporation Bruker drives profitable growth and margin expansion by enabling scientific discoveries and by delivering high-performance analytical, life science and diagnostic solutions Innovation with Integrity Bruker Corporation Safe Harbor Statement Any statements conta
Read more →BRKRBruker Reports Third Quarter 2016 Financial Results
Bruker Reports Third Quarter 2016 Financial Results BILLERICA, Mass. November 2, 2016 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its third quarter ended September 30, 2016. Bruker s revenues for the third quarter of 2016 were $393.9 million, a declin
Read more →BRKRBruker Reports Second Quarter 2016 Financial Results
Bruker Reports Second Quarter 2016 Financial Results BILLERICA, Mass. August 2, 2016 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2016. Bruker s revenues for the second quarter of 2016 were $371.7 million, a decline of
Read more →BRKRBruker Reports First Quarter 2016 Financial Results
Bruker Reports First Quarter 2016 Financial Results BILLERICA, Mass. May 4, 2016 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its first quarter ended March 31, 2016. Bruker s revenues for the first quarter of 2016 were $375.4 million, an increase of 6.
Read more →BRKRBruker Corporation Appoints Anthony Mattacchione as Chief Financial Officer
Bruker Corporation Appoints Anthony Mattacchione as Chief Financial Officer BILLERICA, Mass. February 22, 2016 Bruker Corporation (NASDAQ: BRKR) today announced the appointment of Anthony ( Tony ) Mattacchione as Chief Financial Officer, effective immediately. Mr. Mattacchione
Read more →BRKRBruker Reports Fourth Quarter and Fiscal Year 2015 Financial Results Fiscal Year 2015 (FY-15) GAAP EPS grows 82% year-over-year to $0.60 FY-15 non-GAAP operating margin increases 310 basis points year-over-year to 13.3%
Bruker Reports Fourth Quarter and Fiscal Year 2015 Financial Results Fiscal Year 2015 (FY-15) GAAP EPS grows 82% year-over-year to $0.60 FY-15 non-GAAP operating margin increases 310 basis points year-over-year to 13.3% FY-15 non-GAAP EPS grows 19% year-over-year to $0.89 FY
Read more →BRKRBruker Appoints Robert Rosenthal to Board of Directors
Bruker Appoints Robert Rosenthal to Board of Directors BILLERICA, Mass. November 16, 2015 Bruker Corporation (NASDAQ: BRKR) today announced that it has appointed Dr. Robert Rosenthal to its Board of Directors, effective immediately. Dr. Rosenthal currently serves as Chief Execu
Read more →BRKRBruker Announces New $225 Million Share Repurchase Program
Bruker Announces New $225 Million Share Repurchase Program BILLERICA, Mass. November 13, 2015 Bruker Corporation (NASDAQ: BRKR) today announced that its Board of Directors has approved a new share repurchase program authorizing the purchase of up to $225 million of the Company s
Read more →BRKRBruker Reports Third Quarter 2015 Financial Results Company reports solid organic revenue growth and increased profitability
Bruker Reports Third Quarter 2015 Financial Results Company reports solid organic revenue growth and increased profitability BILLERICA, Mass. November 4, 2015 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its third quarter ended September 30, 2015. Bru
Read more →BRKRBruker Announces Ren Lenggenhager as BioSpin Group President
Bruker Announces Ren Lenggenhager as BioSpin Group President BILLERICA, Massachusetts October 13, 2015 Bruker today announces the appointment of Dr. Ren Lenggenhager as President of the Bruker BioSpin Group, effective November 1st, 2015. Ren has over 25 years of management exper
Read more →BRKRBruker Appoints Mr. John Ornell to Board of Directors
Bruker Appoints Mr. John Ornell to Board of Directors BILLERICA, Mass. August 20, 2015 Bruker Corporation (NASDAQ: BRKR) today announced the appointment of Mr. John Ornell to its Board of Directors, effective August 19, 2015. Mr. Ornell will serve for an initial term expiring at
Read more →BRKRBruker Names Dr. Hermann Requardt to Board of Directors Former CEO of Siemens Healthcare Brings Broad Executive Experience to Board
Bruker Names Dr. Hermann Requardt to Board of Directors Former CEO of Siemens Healthcare Brings Broad Executive Experience to Board BILLERICA, Mass. August 7, 2015 Bruker Corporation (NASDAQ: BRKR) today announced that it has appointed Dr. Hermann Requardt to its Board of Direc
Read more →BRKRBruker Reports Second Quarter 2015 Financial Results
Bruker Reports Second Quarter 2015 Financial Results BILLERICA, Mass. August 5, 2015 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2015. Bruker s revenues for the second quarter of 2015 were $396.0 million, a decline of
Read more →BRKRBruker Announces Resignation of Chief Financial Officer and Appointment of Interim Chief Financial Officer
Bruker Announces Resignation of Chief Financial Officer and Appointment of Interim Chief Financial Officer BILLERICA, Mass. May 20, 2015 Bruker Corporation (NASDAQ: BRKR) today announced that on May 19, 2015, Mr. Charles F. Wagner, Jr., Executive Vice President and the Chief Fin
Read more →BRKRBruker Reports First Quarter 2015 Financial Results
Bruker Reports First Quarter 2015 Financial Results BILLERICA, Mass. May 6, 2015 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its first quarter ended March 31, 2015. Bruker s revenues for the first quarter of 2015 were $353.5 million, a decline of 16.6
Read more →BRKRBruker Reports Fourth Quarter and Full Year 2014 Financial Results
Bruker Reports Fourth Quarter and Full Year 2014 Financial Results BILLERICA, Mass. February 19, 2015 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its fourth quarter and full year ended December 31, 2014. Bruker s revenues for the fourth quarter of 20
Read more →BRKRBruker Reports Third Quarter 2014 Financial Results
Bruker Reports Third Quarter 2014 Financial Results BILLERICA, Mass. November 6, 2014 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its third quarter ended September 30, 2014. Bruker s revenues for the third quarter of 2014 declined by 4.4 percent to $4
Read more →BRKRBruker Reports Second Quarter 2014 Financial Results
Bruker Reports Second Quarter 2014 Financial Results BILLERICA, Mass. August 6, 2014 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2014. Bruker s revenues for the second quarter of 2014 grew by 0.5 percent to $457.4 mil
Read more →BRKRBruker Reports First Quarter 2014 Financial Results
Bruker Reports First Quarter 2014 Financial Results BILLERICA, Mass. May 7, 2014 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its first quarter ended March 31, 2014. Bruker s revenues for the first quarter of 2014 grew by 7.7 percent to $423.7 million,
Read more →BRKRBruker Reports Fourth Quarter and Full Year 2013 Financial Results
Bruker Reports Fourth Quarter and Full Year 2013 Financial Results BILLERICA, Mass. February 18, 2014 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its fourth quarter and full year ended December 31, 2013. Bruker s revenues for the fourth quarter of 20
Read more →BRKRBruker Corporation Announces the Appointment of Dr. Gilles Martin to its Board of Directors
Bruker Corporation Announces the Appointment of Dr. Gilles Martin to its Board of Directors BILLERICA, Massachusetts, January 13, 2014 - Bruker Corporation (NASDAQ: BRKR) announced the election of Dr. Gilles Martin to its Board of Directors, effective as of today. Dr. Martin i
Read more →BRKRBruker Corporation Reports Third Quarter 2013 Financial Results
Bruker Corporation Reports Third Quarter 2013 Financial Results BILLERICA, Mass. November 1, 2013 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its third quarter ended September 30, 2013. Bruker s revenues for the third quarter of 2013 declined by 2.0
Read more →BRKRBruker Corporation Reports Second Quarter 2013 Financial Results Company s financial results rebound after slow start to the year
Bruker Corporation Reports Second Quarter 2013 Financial Results Company s financial results rebound after slow start to the year BILLERICA, Mass. July 31, 2013 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its second quarter ended June 30, 2013. Reve
Read more →BRKRBruker Corporation Reports First Quarter 2013 Financial Results
Bruker Corporation Reports First Quarter 2013 Financial Results BILLERICA, Mass. May 2, 2013 Bruker Corporation (NASDAQ: BRKR) today reported financial results for its first quarter ended March 31, 2013. Revenues for the first quarter of 2013 declined by 3.0 percent to $393.4
Read more →BRKRBruker Corporation Reports Fourth Quarter and Full Year 2012 Financial Results Company delivers year-over-year organic revenue growth of 10 percent and non-GAAP operating income growth of 20 percent in the fourth quarter
Bruker Corporation Reports Fourth Quarter and Full Year 2012 Financial Results Company delivers year-over-year organic revenue growth of 10 percent and non-GAAP operating income growth of 20 percent in the fourth quarter 2012 BILLERICA, Mass. February 19, 2013 Bruker Corporat
Read more →BRKRBruker Reports Financial Results for the Third Quarter of 2012
Bruker Reports Financial Results for the Third Quarter of 2012 BILLERICA, Mass., November 5, 2012 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the third quarter ended September 30, 2012. Bruker Corporation Financial Results In the thir
Read more →BRKRBruker Corporation Reports Financial Results for the Second Quarter and First Half of 2012
Bruker Corporation Reports Financial Results for the Second Quarter and First Half of 2012 BILLERICA, Mass., July 31, 2012 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the three and six months ended June 30, 2012. In the second quarter
Read more →BRKRBruker Announces Preliminary Second Quarter 2012 Revenue and EPS, as well as Planned Earnings Release Date BILLERICA, Mass. (BUSINESS WIRE)
Bruker Announces Preliminary Second Quarter 2012 Revenue and EPS, as well as Planned Earnings Release Date BILLERICA, Mass. (BUSINESS WIRE) July 24, 2012 Bruker Corporation (NASDAQ: BRKR) announced today that based upon preliminary financial data the Company expects total second
Read more →BRKRBruker Corporation Appoints Charles F. Wagner, Jr. as Executive Vice President and New Chief Financial Officer
Bruker Corporation Appoints Charles F. Wagner, Jr. as Executive Vice President and New Chief Financial Officer BILLERICA, Massachusetts, June 7, 2012 (BUSINESS WIRE) - Bruker Corporation (NASDAQ: BRKR) today announced the appointment of Charles F. Wagner, Jr. as its Executive Vi
Read more →BRKRBruker Energy & Supercon Technologies (BEST), Inc. Investor Presentation May 2012 BEST is a wholly owned subsidiary of Bruker Corporation (NASDAQ: BRKR) Think forward Bruker Corporation Safe Harbor Statement 2 Any statem
Burkhard Prause President and CEO 10 years with the Company 2000 2002, Max-Planck Institute, T bingen, Germany: senior staff scientist responsible for planning and operation of several new MRI facilities Ph.D. in Physics, University of Notre Dame Tom Rosa Senior VP and CFO 4 year
Read more →BRKRBruker Corporation Reports First Quarter 2012 Financial Results
Bruker Corporation Reports First Quarter 2012 Financial Results BILLERICA, Mass., May 1, 2012 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the first quarter ended March 31, 2012. First Quarter 2012 Highlights Revenue increased 13.6% ye
Read more →BRKRBruker to Release First Quarter 2012 Financial Results on
Bruker to Release First Quarter 2012 Financial Results on May 1, 2012 BILLERICA, Mass. (BUSINESS WIRE) April 24, 2012 Bruker Corporation (NASDAQ: BRKR) announced today that it plans to release its first quarter 2012 financial results on Tuesday, May 1st, 2012 before the market o
Read more →BRKRBruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2011
Bruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2011 BILLERICA, Mass., February 22, 2012 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and year ended December 31, 2011. Fourth Quarter
Read more →BRKRBruker Corporation (NASDAQ: BRKR) 30th Annual J.P. Morgan Healthcare Conference
EBITDA, Intangible Asset Ratio ~15%; ~$335M (+25%) revenue jump in 2011E, with 2012E-2014E target CAGR of >10% 2009A & 2010A: adj. BSI operating margin up 210 bps and 190 bps, respectively 2014E BSI adj. operating margin goal >18% (excl. new CAM division) 2012E-2014E: Average ann
Read more →BRKRBruker Reports Financial Results for the Third Quarter of 2011
Bruker Reports Financial Results for the Third Quarter of 2011 BILLERICA, Mass., October 27, 2011 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the third quarter ended September 30, 2011. Third Quarter 2011 Financial Highlights: Revenue
Read more →BRKRBruker Appoints William J. Knight as Chief Financial Officer BILLERICA, Mass. (BUSINESS WIRE)
Bruker Appoints William J. Knight as Chief Financial Officer BILLERICA, Mass. (BUSINESS WIRE) September 14, 2011 Bruker Corporation (NASDAQ: BRKR) today announced that William J. ( Bill ) Knight will step back into the Chief Financial Officer role permanently, effective today. B
Read more →BRKRBruker Corporation (NASDAQ: BRKR) Jefferies Field Trip - Investor Presentation
Europe Focus on fast organic growth, disciplined acquisitions and high RoIC Financial Performance 2009-2014E: rapid top-line growth, with major >$300M revenue jump in 2011 2009 & 2010: adjusted operating margin increased 210 bps and 190 bps, respectively 2009-2014E: significant E
Read more →BRKRBruker Corporation Reports Financial Results for the Second Quarter and First Half Year of 2011
Bruker Corporation Reports Financial Results for the Second Quarter and First Half Year of 2011 BILLERICA, Mass., August 3, 2011 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the three and six months ended June 30, 2011. Second Quarter 2
Read more →BRKRBruker Corporation Announces CFO Transition
Bruker Corporation Announces CFO Transition BILLERICA, Massachusetts, June 2, 2011 (BUSINESS WIRE) - Bruker Corporation (NASDAQ: BRKR) announced today that Brian Monahan has stepped down from his position as Bruker s Chief Financial Officer (CFO) for personal reasons, in order t
Read more →BRKRBruker Corporation Reports First Quarter 2011 Financial Results
Bruker Corporation Reports First Quarter 2011 Financial Results BILLERICA, Mass., April 28, 2011 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the first quarter ended March 31, 2011. First Quarter 2011 Highlights Revenue increased 29% y
Read more →BRKRBruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2010
Bruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2010 BILLERICA, Mass., February 23, 2011 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and year ended December 31, 2010. Fourth Quarter
Read more →BRKRBruker Board Meeting
The table reconciles these non-GAAP measures to the most directly comparable GAAP financial measures. INNOVATION WITH INTEGRITY Segment Data Bruker (in millions, except per share amounts) Bruker Energy & Corporate, Consolidated Scientific Supercon Adjustments Bruker Nine Months E
Read more →BRKRBruker Reports Financial Results for the Third Quarter of 2010
Reports Financial Results for the Third Quarter of 2010 BILLERICA, Mass., October 28, 2010 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the third quarter ended September 30, 2010. Third Quarter 2010 Financial increased by 17% year-o
Read more →BRKRBruker Completes Acquisition of the Atomic Force Microscopy and Optical Industrial Metrology Instruments Businesses from Veeco
Bruker Completes Acquisition of the Atomic Force Microscopy and Optical Industrial Metrology Instruments Businesses from Veeco BILLERICA, Mass., October 7, 2010 Bruker Corporation (NASDAQ: BRKR) today announced the closing of its acquisition of the Atomic Force Microscopy (
Read more →BRKRBruker Energy & Supercon Technologies, Inc. Files Registration Statement for Initial Public Offering
Energy & Supercon Technologies, Inc. Files Registration Statement for Initial Public Offering Massachusetts, September 3, 2010 Bruker Corporation ( Bruker ) (NASDAQ: BRKR), a leading global provider of high-performance scientific instruments, and Bruker Energy & Supercon Tech
Read more →BRKRBruker Announces Agreement to Acquire Veeco s Scanning Probe Microscopy (SPM) and Optical Industrial Metrology (OIM) Scientific Instruments Business
Bruker Announces Agreement to Acquire Veeco s Scanning Probe Microscopy (SPM) and Optical Industrial Metrology (OIM) Scientific Instruments Business Massachusetts, August 16, 2010 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today announces the signing of an agreement to
Read more →BRKRBruker Corporation Elects Charles Wagner as Independent Director BILLERICA, Mass. (BUSINESS WIRE)
Bruker Corporation Elects Charles Wagner as Independent Director BILLERICA, Mass. (BUSINESS WIRE) August 3, 2010 Bruker Corporation (NASDAQ: BRKR) today announced the election of Charles F. Wagner, Jr. to its Board of Directors and Audit Committee. Since 2007 until July 2010
Read more →BRKRBruker Corporation Reports Financial Results for the Second Quarter and First Half Year of 2010
Corporation Reports Financial Results for the Second Quarter and First Half Year of 2010 BILLERICA, Mass., July 28, 2010 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the three and six months ended June 30, Second Quarter 2010 Financia
Read more →BRKRBruker Corporation Reports First Quarter 2010 Financial Results
Bruker Corporation Reports First Quarter 2010 Financial Results BILLERICA, Mass., April 29, 2010 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the first quarter ended March 31, 2010. Q1 GAAP Highlights Q1-2010 Q1-2009 Growth Rev
Read more →BRKRBruker and Agilent Technologies Announce Agreement for Bruker to Acquire Certain Varian Inc. Product Lines BILLERICA, Massachusetts and
Agilent Technologies Announce Agreement for Bruker to Acquire Certain Varian BILLERICA, Massachusetts and SANTA CLARA, California March 9, 2010 Bruker Corporation (NASDAQ: BRKR) and Agilent Technologies, Inc. (NYSE:A) announced today that Bruker and Agilent have entered into
Read more →BRKRBruker Corporation Reports Record Financial Results for the Fourth Quarter and Full Year 2009
Bruker Corporation Reports Record Financial Results for the Fourth Quarter and Full Year 2009 BILLERICA, Mass., February 25, 2010 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the fourth quarter and year ended December 31, 2009. Q4 Hi
Read more →BRKRBruker Announces Management Promotions and Strong Fourth Quarter 2009 Preliminary Operating Results
Announces Management Promotions and Strong Fourth Quarter 2009 Preliminary BILLERICA, Mass. February 4, 2010 Bruker Corporation (NASDAQ: BRKR) this week made certain management changes effective, and today announces strong preliminary operating results for its fourth quarter,
Read more →BRKRBruker Corporation (BRKR) 28th J.P. Morgan Healthcare Conference
Superconducting and other subunits for energy research, physics, materials research accelerators Bruker Energy & Supercon Technologies Investment in New Opportunities Bruker Energy & Supercon Technologies (BEST) $36 Million Contract from ITER Fusion Energy Project $36 million con
Read more →BRKRBruker Corporation Appoints William J. Knight to Chief Operating Officer and Brian P. Monahan to Chief Financial Officer
Corporation Appoints William J. Knight to Chief Operating Officer and Brian P. Monahan to Chief Financial Officer Mass. November 9, 2009 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today announced that its Board of Directors has appointed Bill Knight to Chief Operating
Read more →BRKRBruker Corporation Reports Third Quarter 2009 Financial Results
Bruker Corporation Reports Third Quarter 2009 Financial Results BILLERICA, Mass. October 29, 2009 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the third quarter ended September 30, 2009. Third Quarter 2009 Highlights Revenue $265.1
Read more →BRKRBruker Corporation (BRKR) Presentation at Thomas Weisel Partners Healthcare Conference 2009
Elucidation of unexpected or mixed modifications and preparation artefacts Determination of N- & C-termini of intact proteins ETD is an excellent tools for detailed top-down protein characterization PTM mixed modifications preparation artefacts protein termini More detailed prote
Read more →BRKRJapan Special Supplementary Budget (SSB) & Initial Global Stimulus Orders for $10M Received 1. Japan Special Supplemental Budget (SSB) for Science and Technology: 50% allocated to the Ministry of Culture, Sports, Science
Bruker Recently Received Initial Orders >$10M from Global Stimulus: By end of August 2009, stimulus orders for >$10M have been booked in US, Japan and Europe (excluding previous >$12M Japan NPA order) Includes 5 system orders from Japan SSB for > 300M (>$3M, excluding NPA) Additi
Read more →BRKRBruker Corporation Reports Second Quarter 2009 Financial Results
Bruker Corporation Reports Second Quarter 2009 Financial Results BILLERICA, Mass. July 29, 2009 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the second quarter ended June 30, 2009. Second Quarter 2009 Highlights Revenue $252.5 milli
Read more →BRKRBruker Corporation (BRKR) Overview Company Presentation
Results in 2008 and 2007 include charges associated with the acquisition of the Bruker Biospin Group. Under US GAAP, this transaction was accounted for as an acquisition of businesses under common control, and as a result, all one-time transaction costs, including investment bank
Read more →BRKRBruker Corporation (BRKR) Overview Goldman, Sachs 30th Global Healthcare Conference
(d) Results in 2008 include restructuring charges, primarily associated with severance obligations due to headcount reductions. (e) Results in 2008 included in restructuring charges were one time additional German and Swiss income taxes of $1.7 million associated with the liquida
Read more →BRKRBruker Corporation (BRKR) Overview Bank of America & Merrill Lynch 2009 Health Care Conference
MALDI In-Source-Decay Mass Spectrometry A single Edmass spectrum can provide for sequence calls of >80 a.a. residues in seconds Both N- and C-terminals can be assigned using T3-sequencing on Bruker MALDI TOF/TOF Unmatched analysis speed Overcomes other shortcomings of Edman 2009
Read more →BRKRBruker Corporation Reports First Quarter 2009 Results
Bruker Corporation Reports First Quarter 2009 Results BILLERICA, Mass., April 30, 2009 (BUSINESS WIRE) Bruker Corporation (NASDAQ: BRKR) today reported financial results for the first quarter ended March 31, 2009. First Quarter 2009 Snapshot GAAP Revenue decreased 3.3% GAA
Read more →BRKRCopyright 2009 Bruker Corporation. All Rights Reserved. 1 Bruker Corporation (BRKR) Overview JPMorgan Non-Deal Roadshow New York
(c) Results in 2008 and 2007 include charges associated with non-cash stock-based compensation. (d) Results in 2008 include restructuring charges, primarily associated with severance obligations due to headcount reductions. (e) Results in 2008 included in restructuring charges we
Read more →BRKRBruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2008 2008 Highlights Q4-08 FY08 Revenue: $315.2 million $1.107 billion Operating Cash Flow: $86.5 million $105.5 million GAAP EPS per dilu
Bruker Corporation Reports Financial Results for the Fourth Quarter and Full Year 2008 2008 Highlights Q4-08 FY08 Revenue: $315.2 million $1.107 billion Operating Cash Flow: $86.5 million $105.5 million GAAP EPS per diluted share: $0.16 $0.39 Non-GAAP EPS per di
Read more →BRKRBruker Corporation (BRKR) Presentation at 27th J.P. Morgan Healthcare Conference
Investment in New Opportunities: Bruker Advanced Supercon Business Superconducting Wires and Magnets Investment in New Opportunities: Bruker MALDI Molecular Imager MALDI Tissue Imaging and Molecular Histology Complete MALDI Molecular Imaging Solution: For proteins, peptides, lipi
Read more →Competitive Position
How BRKR ranks across every disease it competes inCompetitive Position is a premium feature
See how BRKR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial